Literature DB >> 16100296

The bioequivalence of telithromycin administered orally as crushed tablets versus tablets swallowed whole.

Christina Lippert1, Seth Gbenado, Chunfu Qiu, Bruce Lavin, Steven J Kovacs.   

Abstract

This open-label, randomized, crossover study was conducted to demonstrate bioequivalence for telithromycin administered as crushed or whole tablets. Single 800-mg telithromycin doses (2x400-mg tablets) were administered as crushed tablets mixed in 240 mL nutritional supplement drink followed by 120 mL water or as whole tablets swallowed with 240 mL water. Plasma telithromycin concentrations were measured by liquid chromatography/mass spectrometry; pharmacokinetic parameters were determined using noncompartmental methods. Average bioequivalence criteria were applied. Thirty-two subjects received telithromycin by both methods. The 90% confidence intervals for the geometric mean ratios of maximum plasma concentration and area under the plasma concentration-time curve to 24 hours were within the 0.80 to 1.25 range. Median tmax was 3.00 hours for both treatments. Both methods of administration were well tolerated. Crushing telithromycin tablets and administering them with a nutritional supplement drink is bioequivalent to ingesting whole tablets and could be a viable method of administration for patients unable to swallow tablets whole.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16100296     DOI: 10.1177/0091270005279273

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  2 in total

1.  A Decision Support Tool Facilitating Medicine Design for Optimal Acceptability in The Older Population.

Authors:  Thibault Vallet; Emilie Belissa; Sandra Laribe-Caget; Alain Chevallier; François-Xavier Chedhomme; Patrick Leglise; Matthieu Piccoli; Hugues Michelon; Vanessa Bloch; Sylvie Meaume; Anne-Sophie Grancher; Nathalie Bachalat; Imad Boulaich; Fattima Abdallah; Maite Rabus; Jean-Paul Rwabihama; Annie-Claude Ribemont; Celia Lachuer; Ines Perquy; Laurent Lechowski; Anne Delahaye; Mathieu Depoisson; Yann Orven; Caroline Guinot; Stephane Gibaud; Corinne Michel; Abdel Mahiou; Sid-Ahmed Belbachir; Jean-Hugues Trouvin; Amelie Dufaÿ-Wojcicki; Vincent Boudy; Fabrice Ruiz
Journal:  Pharm Res       Date:  2018-05-07       Impact factor: 4.200

2.  Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.

Authors:  J Martir; T Flanagan; J Mann; Nikoletta Fotaki
Journal:  AAPS PharmSciTech       Date:  2020-10-15       Impact factor: 3.246

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.